Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Green

Showing results (161-170 of 198) with videos related to

Pageof 20
Sort By:
Annals of Surgery|February 10, 2010
Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5Robert C Shamberger, James R Anderson, Norman E Breslow, et al.
Journal of Medicinal Chemistry|January 26, 2010
Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primatesJoseph T Lundquist, Douglas C Harnish, Callain Y Kim, et al.
Pediatric Blood & Cancer|November 6, 2024
The accuracy of estimating equations for the evaluation of kidney function in adult survivors of unilateral, nonmetastatic, non-syndromic Wilms tumor: A pilot study from the St. Jude Lifetime Cohort StudyDaniel M Green, Mingjuan Wang, Matthew J Krasin, et al.
Cancer Treatment Reviews|September 27, 2021
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization groupEdit Bardi, Renée L Mulder, Elvira C van Dalen, et al.
Journal of Medicinal Chemistry|March 11, 2009
Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): an orally active antagonist of the gonadotropin releasing hormone receptor (GnRH-R)Jeffrey C Pelletier, Murty V Chengalvala, Joshua E Cottom, et al.
Medical and Pediatric Oncology|March 29, 2002
Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative projectLeslie L Robison, Ann C Mertens, John D Boice, et al.
Pediatric Blood & Cancer|July 25, 2020
Long-term renal function after treatment for unilateral, nonsyndromic Wilms tumor. A report from the St. Jude Lifetime Cohort StudyDaniel M Green, Mingjuan Wang, Matthew J Krasin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 20, 2021
Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in OncologyFrank Balis, Daniel M Green, Clarke Anderson, et al.
Annals of the American Thoracic Society|July 9, 2016
Pulmonary Function after Treatment for Childhood Cancer. A Report from the St. Jude Lifetime Cohort Study (SJLIFE)Daniel M Green, Liang Zhu, Mingjuan Wang, et al.
The Journal of Clinical Endocrinology and Metabolism|August 3, 2019
Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health OutcomesLaura van Iersel, Zhenghong Li, Deo Kumar Srivastava, et al.
Pageof 20

Showing results (161-170 of 198) with videos related to

Sort By:
Pageof 20
Annals of Surgery|February 10, 2010
Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5Robert C Shamberger, James R Anderson, Norman E Breslow, et al.
Journal of Medicinal Chemistry|January 26, 2010
Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primatesJoseph T Lundquist, Douglas C Harnish, Callain Y Kim, et al.
Pediatric Blood & Cancer|November 6, 2024
The accuracy of estimating equations for the evaluation of kidney function in adult survivors of unilateral, nonmetastatic, non-syndromic Wilms tumor: A pilot study from the St. Jude Lifetime Cohort StudyDaniel M Green, Mingjuan Wang, Matthew J Krasin, et al.
Cancer Treatment Reviews|September 27, 2021
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization groupEdit Bardi, Renée L Mulder, Elvira C van Dalen, et al.
Journal of Medicinal Chemistry|March 11, 2009
Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): an orally active antagonist of the gonadotropin releasing hormone receptor (GnRH-R)Jeffrey C Pelletier, Murty V Chengalvala, Joshua E Cottom, et al.
Medical and Pediatric Oncology|March 29, 2002
Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative projectLeslie L Robison, Ann C Mertens, John D Boice, et al.
Pediatric Blood & Cancer|July 25, 2020
Long-term renal function after treatment for unilateral, nonsyndromic Wilms tumor. A report from the St. Jude Lifetime Cohort StudyDaniel M Green, Mingjuan Wang, Matthew J Krasin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 20, 2021
Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in OncologyFrank Balis, Daniel M Green, Clarke Anderson, et al.
Annals of the American Thoracic Society|July 9, 2016
Pulmonary Function after Treatment for Childhood Cancer. A Report from the St. Jude Lifetime Cohort Study (SJLIFE)Daniel M Green, Liang Zhu, Mingjuan Wang, et al.
The Journal of Clinical Endocrinology and Metabolism|August 3, 2019
Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health OutcomesLaura van Iersel, Zhenghong Li, Deo Kumar Srivastava, et al.
Pageof 20